| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | CTX-10726 Multiple solid tumor indications (PD-1 x VEGF-A bispecific — intended as checkpoint + anti-angiogenesis therapy) | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 1 data readout example | CTX-10726 Multiple solid tumor indications (PD-1 x VEGF-A bispecific — intended as checkpoint + anti-angiogenesis therapy) | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 1 data readout example | CTX-10726 Multiple solid tumor indications (PD-1 x VEGF-A bispecific — intended as checkpoint + anti-angiogenesis therapy) | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Compass Therapeutics, Inc.$2.33
+0.01 (+0.43%)
C 53Pipeline Score Undervalued Biotech · Commercial
Market Cap
372.78 M
EPS
-0.41
P/E Ratio
-
Value Trade
7.28 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
13.39 M
Operating CF
-17.27 M
Total Assets
205.17 M
Total Liabilities
18.70 M
Equity
186.47 M
D/E Ratio
12,345
7.25 %
Week
-61.38 %
1 Month
-67.19 %
3 Month
-57.32 %
6 Month
-51.29 %
5 Year
-75.65 %
All Time
Cash Data
Cash Position
194.69 M
Monthly Burn
5.76 M
Runway
31.8 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
2.80 M
52 Week Range
1.61 - 6.88
% held by Insiders
28.87 %
% held by Institutions
73.18 %
Enterprise Value
187.89 M
Total Shares
177.80 M
Short %
38.4 %
Float Shares
96.72 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Compass Therapeutics, Inc.
302Total events
10Upcoming
61Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 10
Event history 292
Jun 9, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference presentation
Jun 4, 2026
May 30, 2026
◆Poster PresentationCTX-8371Presentation
Poster presentation of Phase 1 dose escalation data for CTX-8371 at ASCO 2026
advanced malignancies (post-checkpoint inhibitor setting)source ↗
May 19, 2026
◆Oral PresentationPresentation
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Apr 27, 2026
◆Oral PresentationCTX-009Presentation
Webcast to review topline secondary endpoints from COMPANION-002 study of tovecimig in BTC
advanced biliary tract cancersource ↗
Apr 27, 2026
▼Full ResultsCTX-009Clinical Data
COMPANION-002 tovecimig overall survival data disclosed
cancersource ↗
Apr 27, 2026
▲Topline ReadoutCTX-009Clinical Data
Key secondary endpoint PFS met: median 4.7 vs 2.6 months (HR=0.44, p<0.0001)
biliary tract cancersource ↗
Apr 27, 2026
▼Secondary Endpoint DataCTX-009Clinical Data
OS secondary endpoint did not meet statistical significance due to crossover
biliary tract cancersource ↗
Drug Pipeline Intelligence
C53
Pipeline Score $718M
Pipeline ValueUndervalued
Valuation Signal5
Drugs Scored6.4x
rNPV / MCap Top 81%
Micro Cap (rank 174 of 911)
Percentile RankCompass Therapeutics, Inc. carries a moderate pipeline score (53/100), with $1.8B risk-adjusted pipeline value, led by CTX-471 in Locally Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTX-471 Small molecule | Locally Advanced Solid Tumor | Phase 1 | NCT03881488 | 5% | $1.6B | COMPLETED | 100 | - | - | May 21, 2025 | - | Apr 17, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CTX-8371 | advanced malignancies | Phase 1 | 2026-05-22 | deep, confirmed, and durable responses observed in patients with NSCLC, TNBC and HL Read More | Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting Read More | |
CTX-8371 | advanced malignancies | Phase 1 | 2026-05-22 | deep, confirmed, and durable responses observed in patients with NSCLC, TNBC and HL Read More | Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting Read More | |
CTX-8371 | advanced malignancies | Phase 1 | 2026-05-22 | deep, confirmed, and durable responses observed in patients with NSCLC, TNBC and HL Read More | Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CMPX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CMPX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CMPX▲ +6.2%on this news
Compass Therapeutics to Participate in Upcoming June Investor Events
Compass Therapeutics, Inc. will participate in two major investor events in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company aims to engage with investors and provide insights into its oncology-focused therapeutic developments. Presentations will be available for replay on their events page.
Read more →CMPX▲ +7.3%on this news· ran to +25% by day 3shared move
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics announced a poster presentation of Phase 1 clinical data for CTX-8371 at the 2026 ASCO Annual Meeting. The data highlights promising responses in patients with advanced malignancies treated after checkpoint inhibitors. The company is expanding cohorts for further study and plans to report additional data later in 2026.
Read more →CMPXCompass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor events in May 2026. The events include the H.C. Wainwright 4th Annual BioConnect Investor Conference and the 2026 Stifel Virtual Targeted Oncology Forum. Management will also be available for one-on-one meetings with interested investors.
Read more →CMPXCompass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its first quarter 2026 financial results, highlighting positive data from its Phase 2/3 study of tovecimig for biliary tract cancer. The company plans to submit a Biologics License Application (BLA) later this year. Additionally, it has ongoing studies for other bispecific antibodies, CTX-8371 and CTX-10726, with promising initial results. Despite a net loss, the company maintains a strong cash position.
Read more →CMPX▼ -64.4%on this news
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Compass Therapeutics announced that tovecimig, in combination with paclitaxel, significantly improved progression-free survival in patients with biliary tract cancer compared to paclitaxel alone. The study met its key secondary endpoint with a median PFS of 4.7 months. However, overall survival results were complicated by a high crossover rate from the control group. The company plans to engage with the FDA for a Biologics License Application submission.
Read more →CMPX▼ -64.4%on this newsshared move
Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims for Compass Therapeutics, Inc. shareholders after the company disclosed that its lead drug candidate did not meet the overall survival secondary endpoint in a recent clinical trial. The median overall survival reported was lower than the control, raising concerns among investors. Following this disappointing news, the stock experienced a significant decline, prompting the investigation into possible federal securities law violations by the company's executive officers. Shareholders who suffered losses are encouraged to reach out for further assistance.
Read more →CMPXCompass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Compass Therapeutics announced it will host a webcast on April 27, 2026, to present topline secondary endpoints from its Phase 2/3 COMPANION-002 study. This clinical study evaluates tovecimig, a bispecific antibody targeting DLL4 and VEGF-A, in combination with paclitaxel for patients with advanced biliary tract cancer. The event highlights the company's commitment to clinical development and investor communication.
Read more →CMPXCompass Health Invites Community to “Camp Out” for Youth Behavioral Health
Compass Health is hosting The Great Compass Health Camp Out on April 17, 2026, to fundraise for its child and youth programs. The event, open to guests 21 and older, will include nostalgic games, camp activities, and speakers sharing impactful stories. This marks the return of Compass Health's annual fundraiser and aims to address the growing behavioral health needs among youth in Northwest Washington. Community members are encouraged to attend and support the organization during these challenging times for behavioral health providers.
Read more →CMPXCompass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Compass Therapeutics reported its 2025 financial results, highlighting significant progress in its clinical trials, particularly with tovecimig in biliary tract cancer. The company has a strong cash position of $209 million, allowing operations into 2028. Upcoming data releases and trial expansions are anticipated to enhance its pipeline and market position.
Read more →CMPXCompass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 5, 2026
Compass Therapeutics has announced the grant of stock options to its new Chief Commercial Officer and Chief Medical Officer as part of its 2025 Inducement Plan. Each executive will receive options to purchase 1,000,000 shares at an exercise price of $5.17, vesting over four years. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to enhance the company's leadership.
Read more →CMPXCompass Therapeutics Provides Corporate Update
Compass Therapeutics provided a corporate update highlighting progress in its clinical pipeline, including advancements in its bispecific antibodies. They expect key analyses of the tovecimig study for biliary tract cancer in late Q1 2026, which may influence future treatments. The company has confirmed durable responses in patients treated with CTX-8371 for various cancers and opened enrollment for cohort expansions. Additionally, with $209 million in cash reserves, Compass is well-positioned to advance its innovative oncology therapies.
Read more →CMPXCompass Therapeutics Announces Key Leadership Appointments
Compass Therapeutics has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, effective January 1, 2026. Both leaders bring extensive experience in oncology, with Prasad's background in product launches and Sirard's expertise in clinical development. Their appointments are expected to strengthen Compass's ability to advance its therapeutic pipeline.
Read more →CMPX▼ -5.3%on this news
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
Compass Therapeutics, a clinical-stage oncology biopharmaceutical company, will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. The company is focused on developing antibody-based therapeutics and will also host investor meetings prior to the conference. Their scientific efforts are centered on targeting critical biological pathways for effective anti-tumor responses.
Read more →CMPXCompass Therapeutics to Participate in Upcoming December Investor Events
Compass Therapeutics, Inc. (Nasdaq: CMPX), an oncology-focused biopharmaceutical company, announced its participation in upcoming investor events in December. The events include the Piper Sandler 37th Annual Healthcare Conference in New York on December 2 and the 8th Annual Evercore Healthcare Conference in Coral Gables on December 4. The company will hold one-on-one meetings with interested investors and will archive the presentations for 90 days. This participation underscores Compass Therapeutics' commitment to engaging with the investment community.
Read more →CMPXCompass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Compass Therapeutics reported its third quarter 2025 financial results, highlighting significant progress in its clinical pipeline, particularly with tovecimig for advanced BTC. The company anticipates reporting overall survival and progression-free survival data in late Q1 2026. Additionally, CTX-8371 has shown promising responses in patients, and the company secured $138 million in financing to support its initiatives.
Read more →CMPXCompass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Compass Therapeutics has announced a poster presentation for CTX-10726 at the SITC Annual Meeting. This bispecific antibody targets PD-1 and VEGF-A, aiming to improve treatment outcomes for cancer patients. The presentation will showcase preclinical data supporting its efficacy in enhancing anti-tumor responses. CTX-10726 is currently undergoing IND-enabling studies.
Read more →CMPXCompass Therapeutics to Participate in Upcoming November Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in several investor events throughout November 2025. These events include the Guggenheim Healthcare Innovation Conference, Stifel Healthcare Conference, and Jefferies Global Healthcare Conference, providing a platform for the company to present its advancements in oncology-focused therapeutics. Presentations will be archived for 90 days for further accessibility.
Read more →CMPXCompass Therapeutics to Participate in Upcoming September Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company, announced its upcoming participation in several prominent investor events throughout September 2025. These events include major conferences hosted by Citi, Cantor, H.C. Wainwright, and Morgan Stanley, which will take place in Boston and New York. The company continues to focus on developing antibody-based therapeutics aimed at oncology and other diseases, highlighting its commitment to advancing its innovative pipeline.
Read more →CMPXCompass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
Compass Therapeutics has announced the pricing of a $120 million public offering of 33,290,000 shares at $3.00 each, along with pre-funded warrants. The proceeds will be used for commercial readiness and clinical development. The offering is expected to close on August 14, 2025, pending customary conditions.
Read more →CMPXCompass Therapeutics Announces Proposed Public Offering
Compass Therapeutics has announced a proposed public offering of its common stock and pre-funded warrants. The proceeds will be used for commercial readiness and clinical development. The offering is subject to market conditions, and there are risks associated with its completion. Jefferies, Piper Sandler, and Guggenheim Securities are managing the offering.
Read more →CMPX▲ +23.7%on this newsshared move
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics has reported its second quarter 2025 financial results and provided updates on its clinical development programs. The ongoing Phase 2/3 study of tovecimig shows fewer deaths than initially expected, suggesting potential improvements in overall survival. Additionally, CTX-8371 has demonstrated promising responses in patients with advanced cancers, prompting plans for cohort expansions. The company ended the quarter with $101 million in cash, ensuring funding for operations into 2027, despite an increase in net losses and R&D expenditures.
Read more →CMPXCompass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
Compass Therapeutics, Inc. (Nasdaq: CMPX) is set to present its second quarter financial results for 2025 on August 11. The company, which focuses on oncology drug development, will also update stakeholders on its ongoing tovecimig Phase 2/3 study and clinical data for CTX-8371 and CTX-10726. This presentation highlights the company's commitment to transparency and progress in their pipeline of antibody-based therapeutics.
Read more →CMPXCompass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compass Therapeutics, Inc. will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025. The company is set to hold a fireside chat on June 5, 2025, at 11:05 AM ET. The event will be available for replay for 90 days on their website. Compass is focused on developing antibody-based therapeutics for oncology.
Read more →CMPXCompass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its first quarter financial results for 2025, highlighting significant progress in its clinical trials, particularly with the bispecific antibody tovecimig, which achieved a promising overall response rate in biliary tract cancer patients. The company successfully dosed the first patient in a trial for tovecimig's use in first-line treatment and continues to advance its other antibodies, including CTX-10726 and CTX-8371. Financially, Compass ended the quarter with $113 million in cash, sufficient to sustain operations through 2027, despite a reported loss of $16.6 million for the quarter, marking a notable increase from the previous year.
Read more →CMPXCompass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
Compass Therapeutics presented promising preclinical data on CTX-471 during the AACR Annual Meeting, showcasing its effectiveness in models resistant to conventional immune checkpoint inhibitors. The study found that when used in combination with tovecimig, CTX-471 markedly increased anti-tumor activity and improved immune system responses. This combination approach may provide a viable treatment option for patients who have previously not responded to checkpoint therapies, indicating significant potential in treating various solid tumors. The CEO expressed excitement about these findings and ongoing research to enhance treatment efficacy across different cancer types.
Read more →CMPXCompass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
Compass Therapeutics has initiated an Investigator Sponsored Trial (IST) for tovecimig, a bispecific antibody, in patients with biliary tract cancer. The trial, conducted at The University of Texas MD Anderson Cancer Center, involves adding tovecimig to a standard treatment regimen for patients with unresectable or metastatic disease. This trial is significant as it evaluates the drug for the first time in a front-line setting. Compass also aims to report secondary endpoint results from an ongoing Phase 2/3 study of tovecimig later this year.
Read more →CMPX▼ -24.6%on this news
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum scheduled for April 8-9, 2025. The company specializes in developing proprietary antibody-based therapeutics aimed at treating various diseases, particularly in oncology. The corporate presentation will be available for streaming and will be archived on the company's website for 90 days following the event. This participation highlights the company's commitment to advancing its therapeutic pipeline and engaging with the oncology community.
Read more →CMPX▲ +17.9%on this newsshared move
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Compass Therapeutics announced that its investigational drug tovecimig (CTX-009) achieved a 17.1% overall response rate in patients with biliary tract cancer when combined with paclitaxel, significantly outperforming paclitaxel alone, which had a 5.3% response rate. The findings were statistically significant, raising hopes for patients with limited second-line treatment options. However, the study is ongoing, and secondary endpoints such as progression-free survival and overall survival have not yet been fully analyzed due to a lack of sufficient events. Detailed safety data and additional study results are anticipated in Q4 2025.
Read more →CMPXCompass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
Compass Therapeutics, Inc. is scheduled to host a webcast on April 1, 2025, to present top-line clinical data from its ongoing Phase 2/3 COMPANION-002 trial. This study evaluates tovecimig, a bispecific antibody, in combination with paclitaxel for patients with advanced biliary tract cancer. The webcast aims to provide insights into the effectiveness of the treatment as part of the company's oncology-focused research efforts.
Read more →CMPXCompass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Compass Therapeutics released its 2024 financial results and provided updates on its clinical pipeline. The company is on track to report top-line data for its Phase 2/3 COMPANION-002 trial of tovecimig by the end of Q1 2025. Additionally, Compass plans to initiate two new Phase 2 trials in mid-2025 for tovecimig and CTX-471. Despite a significant net loss and increases in both R&D and G&A expenses, the company retains a robust cash position to support ongoing and future studies.
Read more →CMPXCompass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced its participation in the Guggenheim Securities SMID Cap Biotech Conference, scheduled for February 5-6, 2025 in New York City. During this conference, the company will present from 9:00 to 9:25 AM EST. Compass is a clinical-stage biopharmaceutical company that is developing antibody-based therapeutics aimed at treating multiple human diseases, particularly in oncology. They have a pipeline focused on exploring key biological pathways for effective anti-tumor responses.
Read more →CMPX▲ +30.1%on this news
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
Compass Therapeutics has provided a corporate update detailing the advancement of its new drug candidate, CTX-10726, along with the expected data readout for its Phase 2/3 trial of tovecimig in biliary tract cancer by the end of Q1 2025. The company is also set to initiate two Phase 2 biomarker trials in mid-2025, targeting DLL4-positive colorectal cancer and NCAM/CD56 expressing tumors. With an estimated cash reserve of $127 million, Compass anticipates a financial runway through Q1 2027, positioning itself well for upcoming clinical developments.
Read more →CMPX▲ +7.9%on this news
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
Compass Therapeutics has appointed Barry Shin as the new Chief Financial Officer, effective December 9, 2024. Mr. Shin brings over 20 years of experience in financial leadership within the biopharmaceutical industry. The company is poised for several critical developments in 2025, notably the topline data readout for CTX-009. Both the CEO and Shin expressed optimism about the company's potential growth and therapeutic advancements as they work towards bringing new options to patients.
Read more →CMPXCompass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Compass Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York City, scheduled for December 3-5, 2024. The company will present on December 4, showcasing its proprietary antibody-based therapeutics aimed at treating various diseases, particularly in oncology. The presentation will focus on their strategies to enhance tumor response through new therapeutic approaches. A webcast of the presentation will be available for 90 days on the company's Events page following the event.
Read more →CMPX▼ -5.6%on this news· ran to -25% by day 3
Compass Therapeutics to Participate in Upcoming Investor Events
Compass Therapeutics, Inc. will participate in two notable investor events this month, including the Stifel 2024 Healthcare Conference in New York and the Jefferies London Healthcare Conference. These events are expected to provide the company with a platform to discuss its proprietary antibody-based therapeutics aimed at treating various human diseases. The presentations will be accessible via webcasts and will remain archived for 90 days. This engagement highlights Compass’s commitment to advancing its clinical-stage pipeline.
Read more →CMPX▼ -5.8%on this news· ran to -27% by day 3shared move
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its financial results for the third quarter of 2024 and provided updates on its clinical programs. The company's lead asset, CTX-009, has fully enrolled in a Phase 2/3 trial for biliary tract cancers, with top-line data expected by the end of Q1 2025. Significant advancements were made in understanding biomarkers related to CTX-471 and plans for further trials are set for mid-2025. Despite a reported net loss for the quarter, Compass maintains a healthy cash position projected to last until early 2027.
Read more →CMPXCompass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Compass Therapeutics presented new biomarker data at the SITC Annual Meeting, revealing a correlation between neural cell adhesion molecule (NCAM) levels and patients' responses to CTX-471. The analysis from a Phase 1 trial showed that NCAM expression may be instrumental in predicting treatment efficacy, potentially paving the way for expanded indications. The company is now planning a Phase 2 trial focusing on patients with NCAM-expressing tumors, furthering their clinical development strategy.
Read more →CMPXCompass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Compass Therapeutics, Inc. has announced the acceptance of its abstract for a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer Annual Meeting. The presentation will focus on pharmacodynamic and response biomarkers from a Phase 1 trial of CTX-471, a novel anti-CD137 agonist antibody. The annual meeting will take place from November 8-10, 2024, in Houston, Texas. This acknowledgment highlights the company's commitment to advancing cancer treatment through innovative antibody-based therapeutics.
Read more →CMPXCompass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its second quarter 2024 financial results along with a corporate update. The company completed enrollment in its COMPANION-002 study, focusing on the CTX-009 treatment for biliary tract cancers, with top-line results anticipated in Q1 2025. Preliminary data from ongoing trials show promising survival rates for advanced colorectal cancer patients treated with CTX-009. Furthermore, they are planning additional trials for CTX-471 and CTX-8371 while addressing an increase in R&D costs and a net loss in the latest financial period.
Read more →CMPX▼ -6.5%on this news· ran to +17% by day 3shared move
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced its participation in the Wedbush PacGrow Healthcare Conference, scheduled for August 13, 2024, in New York City. At this event, the company will present its advancements in proprietary antibody-based therapeutics targeting cancer. Compass Therapeutics aims to develop treatments by focusing on the relationship between angiogenesis and the immune response to tumors. This opportunity highlights the company’s ongoing efforts to advance its product pipeline in the oncology field.
Read more →CMPXCompass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Compass Therapeutics has successfully completed patient enrollment for the COMPANION-002 trial, which involves 150 patients with unresectable advanced Biliary Tract Cancer. In addition to this milestone, the company announced the initiation of an Investigator Sponsored Trial (IST) for CTX-009 in a first-line setting, expanding its clinical research efforts. CTX-009, which targets critical pathways involved in tumor vascularization, aims to improve outcomes for patients who have previously undergone chemotherapy. This trial will be conducted in collaboration with MD Anderson Cancer Center.
Read more →CMPXCompass Pathways announces second quarter 2024 financial results and business highlights
Compass Pathways reported its financial results for Q2 2024, highlighting a net loss of $38.1 million. The company announced the appointment of new leadership including Gino Santini as Chairman and Lori Englebert as Chief Commercial Officer. Positive results from a phase 2 study of COMP360 for PTSD were shared, and top-line data from the pivotal phase 3 program for treatment-resistant depression is anticipated by Q4 2024. The company maintains a strong cash position of $228.6 million to fund ongoing operations.
Read more →CMPXCompass Pathways appoints Lori Englebert as Chief Commercial Officer
Compass Pathways has appointed Lori Englebert as Chief Commercial Officer, effective July 8, 2024. Englebert, who previously held significant roles in global pharmaceuticals, will join an executive team that includes a new CFO and Chief R&D Officer. This appointment comes ahead of pivotal study results and potential regulatory approvals for the company's COMP360 psilocybin treatment, which aims to provide innovative solutions for treatment-resistant depression.
Read more →CMPXCompass Therapeutics Announces CEO Transition
Compass Therapeutics, Inc. has announced a leadership transition as Thomas Schuetz, M.D., Ph.D. has been appointed as the new President and CEO, effective May 28, 2024. Schuetz, who previously served as President of Research and Development, expressed eagerness to push forward with the company's clinical programs. The former CEO, Vered Bisker-Leib, has stepped down but will remain with the company as a Senior Consultant for the next 15 months, ensuring a smooth transition.
Read more →CMPXCompass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
Compass Therapeutics has announced promising Phase 1 trial results for its anti-CD137 agonist antibody, CTX-471, showing anti-tumor activity in patients with advanced malignancies who previously received PD-1/PD-L1 inhibitors. The trial recorded five clinical responses, including a complete response in a small-cell lung cancer patient. CTX-471 was well tolerated, with a low incidence of adverse events, primarily being low grade. This novel treatment option highlights potential benefits for patients who have limited alternatives in advanced settings.
Read more →CMPXCompass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Compass Therapeutics, Inc. (Nasdaq: CMPX), a biopharmaceutical company specializing in oncology, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024. The event will include a fireside chat and a corporate presentation that will be available for 90 days post-event. The company, headquartered in Boston, focuses on developing antibody-based therapeutics to target various pathways for anti-tumor responses.
Read more →CMPXCompass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its first quarter financial results for 2024, highlighting several advancements in its clinical pipeline. The company received FDA Fast Track Designation for CTX-009 in treating advanced biliary tract cancer, with ongoing enrollment in its Phase 2/3 trial. Additionally, it completed enrollment in a Phase 2 study for CTX-009 in advanced colorectal cancer and advanced CTX-8371 to a first-in-human trial. The financial report indicated a net loss of $10.8 million, though the company retains a solid cash position of $156 million.
Read more →CMPX▼ -6%on this newsshared move
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
Compass Pathways plc reported its financial results for Q1 2024, highlighting positive phase 2 data for COMP360 psilocybin treatment in PTSD. The company is advancing its phase 3 pivotal program for treatment-resistant depression, with top-line data expected in Q4 2024. Additionally, Compass has raised $63.5 million in net cash during the first quarter and is establishing new collaborations for the treatment's delivery. Despite increased losses, the cash position is robust, projected to fund operations through 2026.
Read more →CMPXCompass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Compass Therapeutics has received FDA Fast Track Designation for its bispecific DLL4/VEGF-A antibody, CTX-009, in combination with paclitaxel. The designation aims to expedite the development and review of the treatment for patients with metastatic or locally advanced biliary tract cancer who have prior treatments. The recent Phase 2 study demonstrated a 37.5% response rate among patients, indicating a potentially significant therapeutic impact. With top-line data from an ongoing Phase 2/3 study expected by the end of 2024, the company aims to address the unmet medical needs in this patient population.
Read more →CMPXCompass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics announced that the first patient has been dosed in a Phase 1 clinical trial for CTX-8371, a bispecific antibody targeting PD-1 and PD-L1. This trial is intended for patients with advanced solid tumors who have experienced progression after prior treatments. The company highlighted CTX-8371's novel mechanism, which reportedly leads to improved anti-tumor activity compared to existing checkpoint inhibitors. This milestone marks the advancement of Compass's third program into clinical development.
Read more →CMPXCompass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
Compass Therapeutics, Inc. announced its participation at the Cholangiocarcinoma Foundation 2024 Annual Conference, where they will present research on their bispecific antibody, CTX-009. Two posters will be presented, focusing on the introduction of CTX-009 and a study on patient selection utilizing real-world cancer data. The conference will take place from April 17 to 19, 2024, in Salt Lake City, Utah. Access to the presentation materials will be available on the company’s website post-conference.
Read more →CMPXCompass Therapeutics to Participate in the Stifel Targeted Oncology Days
Compass Therapeutics, Inc. announced its participation in the Stifel Targeted Oncology Days, a virtual event scheduled for April 16-17, 2024. The presentation will highlight the company's proprietary antibody-based therapeutics designed to treat various human diseases. The webcast link will be available for attendees, and the presentation will be archived on the company's events page for 90 days. This participation underlines Compass's ongoing efforts to advance its clinical pipeline in oncology.
Read more →CMPXCompass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Compass Therapeutics, Inc. presented data at the 2024 AACR Annual Meeting showcasing the effectiveness of their bispecific antibody, CTX-009, combined with CTX-471 in eliminating MHC-I negative tumors in preclinical models. This combination therapy showed superior anti-tumor activity compared to either treatment alone, potentially offering new hope for patients who have progressed on existing checkpoint inhibitor therapies. The results suggest that the approach could enhance NK cell activity against tumors lacking MHC-I, addressing a critical gap in current cancer treatments.
Read more →CMPX▲ +5.7%on this news
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Compass Therapeutics recently reported its 2023 financial results and provided a corporate update, highlighting progress in its clinical studies, particularly for its lead drug, CTX-009. Enrollment in two major trials, COMPANION-002 and COMPANION-003, is ongoing with expected data releases in 2024. The company also plans to initiate additional studies for CTX-471 and has advanced CTX-8371 into a Phase 1 trial. Despite a net loss of $42.5 million for the year, Compass ended 2023 with a solid cash position that secures its operational runway into mid-2026.
Read more →CMPXCompass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Compass Therapeutics, Inc. announced its participation in the upcoming Leerink Partners Global Biopharma Conference scheduled for March 13, 2024, in Miami Beach, Florida. This event will provide the company with an opportunity to present its proprietary antibody-based therapeutics focused on oncology. The corporate presentation will be archived for 90 days on its events page, allowing broader access for interested parties. With its focus on critical pathways in tumor growth and immune response, Compass aims to advance its clinical-stage product candidates at the conference.
Read more →CMPXCompass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
Compass Therapeutics has announced the publication of preclinical data for CTX-8371, a novel bispecific checkpoint inhibitor targeting PD-1 and PD-L1. The data reveals that CTX-8371 shows enhanced anti-tumor activity compared to existing therapies, and its combination with CTX-471 further improves efficacy in preclinical models. The article was published in the journal OncoImmunology, and Compass plans to begin first-in-human clinical trials shortly, following FDA clearance of their Investigational New Drug application. These developments highlight the therapeutic potential of CTX-8371 in oncology.
Read more →CMPX▲ +5.2%on this news· ran to +17% by day 3
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
Compass Pathways and Greenbrook TMS have initiated a three-year research collaboration to investigate the delivery models for the COMP360 psilocybin treatment, pending FDA approval. The focus will be on enhancing treatment accessibility for individuals with treatment-resistant depression and other mental health conditions. This partnership aims to optimize the integration of innovative therapies within healthcare systems and improve patient care experiences. The COMP360 has been designated as a Breakthrough Therapy by the FDA, and Compass is also advancing its phase 3 clinical program in TRD.
Read more →CMPX▼ -6.4%on this news
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Compass Therapeutics, Inc. reported its financial results for the third quarter of 2023, highlighting advancements in its clinical trials and drug development. The company opened 29 clinical sites for its COMPANION-002 and is progressing with COMPANION-003. They received FDA clearance for CTX-8371 and plan to initiate a first-in-human study soon. Financially, Compass ended the quarter with $164 million, ensuring operational continuity into 2026 despite reporting a net loss of $10 million.
Read more →CMPXCompass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Compass Therapeutics reported its second-quarter financial results and provided updates on its clinical studies. The company is actively enrolling patients in a Phase 2 study of CTX-009 for advanced colorectal cancer, with data expected later this year, while recruitment for its biliary tract cancer study has been slower than planned. They also announced the completion of the dose-escalation study for CTX-471 and expect to file an IND for CTX-8371 shortly. The company ended the quarter with $169 million in cash, providing a strong runway for continued operations.
Read more →CMPXCompass Therapeutics to be Added to the Russell 2000 and Russell 3000 Indexes
Compass Therapeutics, Inc. announced its upcoming inclusion in the Russell 2000® and Russell 3000® Indexes, effective June 26, 2023. This membership, granted through FTSE Russell's annual reconstitution, is anticipated to enhance stock trading activity and broaden exposure to potential investors. The company specializes in developing proprietary antibody-based therapeutics aimed at treating various human diseases, particularly in the realm of oncology. As a clinical-stage company, Compass is focused on advancing its product pipeline to improve patient outcomes in cancer treatment.
Read more →CMPXCompass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics has reported its first quarter financial results and provided an update on its clinical development activities. The company has initiated patient enrollment in a Phase 2/3 study of CTX-009 for advanced biliary tract cancers, with top-line data expected in 2024, while initial data for another colorectal cancer study is anticipated in Q3 2023. Additionally, the company has strengthened its leadership team with key appointments and ended the quarter with a solid cash position of $175 million. However, they reported a net loss of $7.8 million, highlighting increased R&D expenditures.
Read more →CMPXCompass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Compass Therapeutics, Inc. is set to participate in the H.C. Wainwright BioConnect Investor Conference, scheduled for May 2, 2023, in New York City. The conference will feature a fireside chat that will be accessible via webcast, with the presentation archived for 90 days for further viewing. The company, which specializes in developing antibody-based therapeutics for oncology, aims to strengthen its investor relations and showcase its pipeline of innovative treatments. Established in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics continues to pursue advancements in targeting cancer through its novel therapies.
Read more →CMPX▼ -5%on this news
Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
Compass Therapeutics, Inc. will participate in the Stifel 2023 Virtual Targeted Oncology Days on April 25-26, 2023. The event highlights the company's focus on developing innovative antibody-based therapeutics for oncology. The company’s pipeline targets key biological pathways for effective anti-tumor responses. Following the event, the corporate presentation will be available for 90 days on their website.
Read more →CMPXCompass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium
Compass Therapeutics, Inc. will participate in the Cantor Fitzgerald Future of Oncology Symposium taking place virtually from April 3 to 5, 2023. The company specializes in developing proprietary antibody-based therapeutics aimed at treating various diseases related to oncology. Their research focuses on the interplay between angiogenesis, the immune system, and tumor growth, indicating their commitment to advancing cancer treatment through innovative approaches.
Read more →CMPXCompass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Compass Therapeutics reported its fourth quarter and full year 2022 financial results, highlighting advancements in its drug candidate programs. The company initiated a Phase 2/3 study of its bispecific antibody CTX-009 for biliary tract cancers and a Phase 2 study for colorectal cancer. Significant progress has been made in other trials, including a successful enrollment in Phase 1 studies for CTX-471. Compass ended the year with $187 million in cash, indicating strong funding to support future developments.
Read more →CMPXCompass Therapeutics to Participate in the SVB Securities Global Biopharma Conference
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on oncology, announced its participation in the upcoming SVB Securities Global Biopharma Conference scheduled for February 13-16, 2023. The company is set to host a fireside chat on February 15, and the presentation will be available for replay for 90 days. Compass Therapeutics is known for its development of antibody-based therapeutics targeting critical biological pathways involved in tumor response and immunotherapy.
Read more →CMPX▼ -10.9%on this news
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
Compass Therapeutics announced positive data regarding CTX-009 when combined with paclitaxel for treating biliary tract cancers (BTC) in a Phase 2 trial. The combination therapy demonstrated a 37.5% overall response rate among treated patients, with a median progression-free survival of 9.4 months and a median overall survival of 12.5 months. A randomized Phase 2/3 study of CTX-009 is being initiated in the U.S., which could lead to regulatory submissions in 2024, depending on the outcomes. The findings highlight CTX-009’s potential amidst a landscape of limited treatment options for advanced BTC patients.
Read more →CMPXCompass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer
Compass Therapeutics announced that the first patient has been dosed in the Phase 2 study of CTX-009 for metastatic colorectal cancer in the U.S. This study targets patients who have exhausted previous treatment options, highlighting the need for new therapies. CTX-009 is being evaluated for safety and efficacy, with early promising results from earlier phases. The success of this trial is contingent on achieving confirmed responses in a limited patient cohort, with results anticipated in mid-2023.
Read more →CMPXCompass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21
BOSTON, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that updated results from the ong
Read more →CMPX▲ +11.9%on this news
Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA (pembrolizumab)
First patient dosed in Phase 1b study of CTX-471 in combination with KEYTRUDA® in cancers of the lung, head and neck, as well as melanoma In the first part of this Phase 1b study, CTX-471 was dosed as a monotherapy and demonstrated signs of activity in patients with various meta
Read more →CMPXCompass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the Piper Sandler 34th Annual H
Read more →CMPXCompass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Study site initiations in the United States for a randomized Phase 2/3 study of CTX-009 with paclitaxel in patients with Biliary Tract Cancers (BTC) and a Phase 2 of CTX-009 in patients with Colorectal Cancer (CRC) are ongoing; patient enrollment for both studies is expected duri
Read more →CMPX▲ +10.1%on this newsshared move
Compass Therapeutics to Present at Upcoming Investment Conferences
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will be presenting at the following investor conferences during t
Read more →CMPX▲ +10.5%on this news
Compass Therapeutics Announces $80 Million Private Placement
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it has entered into a securities purchase agreemen
Read more →CMPX▲ +8.8%on this news
Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA (pembrolizumab)
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced a clinical trial collaboration and supply agreement with Merck (know
Read more →CMPXCompass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the 24th Annual H.C. Wainwrigh
Read more →CMPXCompass Health Center to Host Free Educator and Clinician Webinar/CEU: Understanding and Treating School Anxiety & Refusal, Aug. 25, 2022, 10 AM Central Time (US and Canada)
NORTHBROOK, Ill., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Compass Health Center will be hosting a live webinar/CEU on Aug. 25, 2022, at 10 a.m. CT. The webinar, titled "Understanding and Treating School Anxiety & Refusal," is for clinicians and education professionals working with chil
Read more →CMPXCompass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will present at the 2022 Wedbush PacGrow Healthcare Conference th
Read more →CMPXCompass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Phase 2/3 trial of CTX-009 (DLL4 X VEGF-A bispecific) and paclitaxel in biliary tract cancer (BTC) anticipated to begin in the United States in Q3 2022 A Phase 2 trial of CTX-009 as a monotherapy in advanced colorectal cancer (CRC) is on track to begin in Q4 2022 A fourth parti
Read more →CMPXCompass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will present at the 2022 Jefferies Global Healthcare Conference th
Read more →CMPX▲ +6.6%on this news
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, M.D., Ph.D., Co-founder and Chief Executive Office
Read more →CMPXCompass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract cancer (BTC) to a global study and initiate dosing patients in the United States in e
Read more →CMPXCompass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11:20 a.m. PT
BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, M.D., Ph.D., Co-founder, and Chief Executive Offic
Read more →CMPXCompass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers
CTX-009 Demonstrated a 42% Overall Response Rate (ORR) Based on 10 Partial Responses (PRs) in 24 Enrolled Patients CTX-009 Continues to be Well Tolerated, Consistent with the Phase 1 Studies Compass Plans to Initiate Stage 2 of the Phase 2 Study in the U.S. in Q3 2022 Compass
Read more →CMPXCompass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009
Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat
Read more →CMPXCompass Therapeutics Announces Appointment of Two New Directors to its Board
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today is pleased to announce the appointment of
Read more →CMPX▼ -6.7%on this news
Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported new preclinical data on CTX-8371, a ne
Read more →CMPX▲ +5.6%on this news· ran to +27% by day 3
Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced today that it will present preclinical data
Read more →CMPX▲ +6.2%on this news
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Ended 2021 with $144.5 million in cash and cash equivalents CTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well; the response criteria required to advance the study to its second stage have be
Read more →CMPX▼ -5.3%on this news· ran to -27% by day 3
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)
BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its IND
Read more →CMPXCompass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market Boston
Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market Boston, November 1, 2021 Compass Therapeutics, Inc. (the Company ), a clinical-stage biopharmaceutical company developing proprietary antib
Read more →CMPXCompass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle  Phase 2a study was initiated by
Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle Phase 2a study was initiated by Handok Pharmaceuticals in Q1 2021 in patients with Biliary Tract Ca
Read more →CMPXCTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics  CTX-009 was w
CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics CTX-009 was well tolerated and demonstrated single agent activity in heavily pre-
Read more →CMPXCompass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc. To Obtain Global Rights to TR009, A Novel bispecific antibody and Inhibitor of the Notch Pathway Targeting DLL4 and VEGF-A BOSTON & IRVINE, Calif. May 13 th
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc. To Obtain Global Rights to TR009, A Novel bispecific antibody and Inhibitor of the Notch Pathway Targeting DLL4 and VEGF-A BOSTON & IRVINE, Calif. May 13th , 2021 - (BUSINESS WIRE) - Compass Therapeutics, Inc. ("Com
Read more →CMPXCOMPASS PATHWAYS (NASDAQ:CMPS) IPO PROVES PSYCHEDELIC MEDICINE INVESTMENT THESIS
New York City, Oct. 01, 2020 (GLOBE NEWSWIRE) -- WPSS Investments, a pioneer biotech Venture Capital fund focused on brain health and psychedelic medicine, celebrates the successful IPO of its portfolio company Compass Pathways. On September 18th, 2020 Compass Pathways was liste
Read more →CMPXCompass Therapeutics, Inc. Provides Corporate Update CAMBRIDGE, Mass., September 15th, 2020 Compass Therapeutics, Inc. a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engag
Compass Therapeutics, Inc. Provides Corporate Update CAMBRIDGE, Mass., September 15th, 2020 Compass Therapeutics, Inc. a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematol
Read more →CMPXCompass Therapeutics LLC and Subsidiary Consolidated Financial Statements December 3 1, 2019 and 2018 Compass Therapeutics LLC and Subsidiary Index
Therapeutics LLC and Subsidiary Financial Statements Therapeutics LLC and Subsidiary Page(s) Report of Independent Registered Public Accounting Firm 1 Consolidated Financial Statements Consolidated Balance Sheets 2 Consolidated Statements of Operations 3 Consolidated Stateme
Read more →CMPXCompass Cannabis Clinics Launches International Venture
CALGARY, Alberta, June 11, 2018 (GLOBE NEWSWIRE) -- 10330698 Canada Ltd. (dba Compass Cannabis Clinics, "Compass") is pleased to announce that it has entered into a letter of intent with Dr. Teresa Towpik which will signal the launch of its operations in Australia under a joint v
Read more →Competitive Position
How CMPX ranks across every disease it competes inCompetitive Position is a premium feature
See how CMPX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial